aTen Therapeutics is focused on developing innovative therapeutic antibodies, particularly their lead candidate, TENSINUMAB (ATN-E11). This novel human monoclonal antibody is designed to target the angiotensin-II type I receptor (AT1R), which is known to be overexpressed in various cancers. By selectively modulating this receptor, ATN-E11 has demonstrated significant efficacy in inhibiting tumor growth and prolonging survival in experimental cancer models. The company utilizes phage display technology to generate this antibody, which enhances its specificity and effectiveness against cancer cells.

In addition to its oncology applications, aTen Therapeutics is exploring the broader potential of ATN-E11 in treating other major health conditions where AT1R overexpression contributes to disease severity and progression. The company has received funding from Innovate UK to accelerate the development of ATN-E11 in collaboration with scientists at Anglia Ruskin University. With a commitment to advancing their technology, aTen Therapeutics aims to provide powerful new treatment options that can extend and improve the lives of patients affected by various diseases.

United Kingdom

aTen Therapeutics is an innovative biotechnology company developing novel therapeutic antibodies to target a fundamental control pathway associated with cancer and several other major diseases. Their technology is focused on antibody discovery and cutting-edge technology development.

aTen Therapeutics

Company Details